SLC2A1 and cancer: Additionally, SLMP53-1 inhibited glycolysis, with downregulation of several glycolytic intervenient, including glucose transporters (GLUT1) and enzymes (HK2 and PFKFB3), which are direct p53 targets, in cancer cells and xenograft tumor tissue.